Clinical Trial Update: A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD [Phase 3]

View source ↗

Summary

A 12-week Phase 3 trial comparing QVA149 (indacaterol/glycopyrronium) to Fluticasone/Salmeterol (Advair) for COPD was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone/Salmeterol (fluticasone/salmeterol)
• QVA149 (indacaterol/glycopyrronium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: WITHDRAWN